References
- Chen, C., and Sun, L. (2011), “Quantification of PFS Effect for Accelerated Approval of Oncology Drugs,” Statistics in Biopharmaceutical Research, 3, 434–444. DOI: 10.1198/sbr.2011.09046.
- Chen, C., Anderson, K., Mehrotra, D. V., Tse, A., and Rubin, E. H. (2018), “A 2-in-1 Adaptive Phase 2/3 Design for Expedited Drug Development,” Contemporary Clinical Trials, 64, 238–242. DOI: 10.1016/j.cct.2017.09.006.
- Chen, C., Sun, L., and Chih, C. (2013), “Evaluation of Early Efficacy Endpoints for Proof-of-Concept Trials,” Journal of Biopharmaceutical Statistics, 23, 413–424. DOI: 10.1080/10543406.2011.616969.
- Deng, Q., Bai, X., and Ting, N. (2018), “Dynamic Development Paths for Expanding a Proof-of-Concept Study to Explore Dose Range,” Statistics in Medicine, 37, 3244–3253. DOI: 10.1002/sim.7840.
- Galbraith, S., and Marschner, I. C. (2003), “Interim Analysis of Continuous Long-Term Endpoints in Clinical Trials with Longitudinal Outcomes,” Statistics in Medicine, 22, 1787–1805. DOI: 10.1002/sim.1311.
- Jin, M., and Zhang, P. (2021), “A Seamless Adaptive 2-in-1 Design Expanding a Phase 2 Trial for Treatment or Dose Selection into a Phase 3 Trial,” Statistics in Biopharmaceutical Research, 14, 334–341. DOI: 10.1080/19466315.2021.1914717.
- Kay, S. R., Fiszbein, A., and Opler, L. A. (1987), “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,” Schizophrenia Bulletin, 13, 261–276. DOI: 10.1093/schbul/13.2.261.
- Kunz, C. U., Friede, T., Parsons, N., Todd, S., and Stallard, N. (2014), “Data-Driven Treatment Selection for Seamless Phase II/III Trials Incorporating Early-Outcome Data,” Pharmaceutical Statistics, 13, 238–246. DOI: 10.1002/pst.1619.
- Kunz, C. U., Friede, T., Parsons, N., Todd, S., and Stallard, N. (2015), “A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints,” Journal of Biopharmaceutical Statistics, 25, 170–189.
- Marschner, I. C., and Becker, S. L. (2001), “Interim Monitoring of Clinical Trials based on Long-Term Binary Endpoints,” Statistics in Medicine, 20, 177–192. DOI: 10.1002/1097-0258(20010130)20:2<177::AID-SIM653>3.0.CO;2-K.
- Sun, L. Z., Li, W., Chen, C., and Zhao, J. (2019), “Advanced Utilization of Intermediate Endpoints for Making Optimized Cost-Effective Decisions in Seamless Phase II/III Oncology Trials,” Statistics in Biopharmaceutical Research, 12, 224–233. DOI: 10.1080/19466315.2019.1665578.
- Wüst, K., and Kieser, M. (2003), “Blinded Sample Size Recalculation for Normally Distributed Outcomes Using Long- and Short-term Data,” Biometrical Journal, 45, 915–930. DOI: 10.1002/bimj.200390060.